Ind-Swift Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories submitted its Q1 FY26 results. Standalone revenue from operations rose about 2.6% YoY to Rs 147.99 crore (vs Rs 144.31 crore), but total income fell roughly 13% to Rs 162.58 crore from Rs 187.38 crore, mainly because the year-ago quarter included a one-time exceptional gain of Rs 215.88 crore from the merger scheme. Standalone profit after tax came in at Rs 8.12 crore (vs Rs 218.09 crore, inflated by the exceptional item); on a pre-exceptional basis, profit before tax was nearly flat at Rs 9.83 crore vs Rs 10.27 crore. Consolidated PAT was Rs 8.77 crore (vs Rs 29.17 crore). The board also noted that the amalgamation of Ind-Swift Limited with the company became effective on August 8, 2025, with an appointed date of March 31, 2024, and 81.25 lakh new ISLL shares will be issued to ISL shareholders on the record date of August 14, 2025. Three subsidiaries' interim numbers included in the consolidated results were not reviewed by their auditors.
The sharp YoY drop in headline profit looks alarming but is almost entirely due to the large one-time merger-related gain booked in the year-ago quarter; core operations are broadly stable. The completed merger with Ind-Swift Limited will expand the consolidated entity going forward, and shareholders should watch the share allotment and any related dilution impact.